FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116156965> ?p ?o ?g. }

• W2116156965 endingPage "722" @default.
• W2116156965 startingPage "714" @default.
• W2116156965 abstract "Multiple myeloma is an incurable disease with heterogeneous clinical behavior. Bortezomib has offered some patients with relapsed and refractory disease an opportunity for prolonged survival. However, there remains a paucity of data in patients treated with bortezomib that accurately delineates and identifies such patients. This information is crucial to guide management.In this study, we aimed to identify the patients most likely to respond to bortezomib salvage therapy. We analyzed the baseline clinical variables and profiled the baseline expression of a broad range of immunohistochemical markers of cell cycle activity, apoptosis, and angiogenesis in a large cohort of multiply relapsed myeloma patients recruited to one of two prospective multicentre trials assessing the efficacy of bortezomib salvage therapy.Using the European Group for Bone Marrow Transplantation criteria, response (complete or partial) to bortezomib salvage therapy was associated with a previous history of complete response to alternative antimyeloma treatment. Patients who expressed cyclin D1 were more likely to achieve a response. In contrast, patients who expressed p16(INK4A), cytoplasmic p53, and the highest intensity of Bcl-2 staining had a poor response. Patients who achieved a response to bortezomib and those patients who expressed cyclin D1 at baseline showed a significant survival advantage. Patients who expressed FGFR3, a poor prognostic marker, responded equally well and had similar outcomes with bortezomib compared with FGFR3-negative patients.Baseline clinical variables and selective immunohistochemical markers expressed by patients may be used effectively to identify patients that are most likely to achieve a meaningful clinical response to bortezomib salvage therapy." @default.
• W2116156965 created "2016-06-24" @default.
• W2116156965 creator A5002073335 @default.
• W2116156965 creator A5023128779 @default.
• W2116156965 creator A5031193094 @default.
• W2116156965 creator A5033407869 @default.
• W2116156965 creator A5050350842 @default.
• W2116156965 creator A5054461576 @default.
• W2116156965 creator A5058771300 @default.
• W2116156965 creator A5066578976 @default.
• W2116156965 creator A5067860129 @default.
• W2116156965 creator A5069441736 @default.
• W2116156965 creator A5074102777 @default.
• W2116156965 creator A5090258495 @default.
• W2116156965 date "2009-01-15" @default.
• W2116156965 modified "2023-10-14" @default.
• W2116156965 title "Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma" @default.
• W2116156965 cites W1887989049 @default.
• W2116156965 cites W1944291718 @default.
• W2116156965 cites W1946894092 @default.
• W2116156965 cites W1980471295 @default.
• W2116156965 cites W1992538067 @default.
• W2116156965 cites W1995457775 @default.
• W2116156965 cites W1997478952 @default.
• W2116156965 cites W1998922870 @default.
• W2116156965 cites W2017303578 @default.
• W2116156965 cites W2025383700 @default.
• W2116156965 cites W2026043555 @default.
• W2116156965 cites W2029006246 @default.
• W2116156965 cites W2030808959 @default.
• W2116156965 cites W2039374629 @default.
• W2116156965 cites W2041403839 @default.
• W2116156965 cites W2057942504 @default.
• W2116156965 cites W2061196972 @default.
• W2116156965 cites W2065628269 @default.
• W2116156965 cites W2072454080 @default.
• W2116156965 cites W2073981334 @default.
• W2116156965 cites W2076028786 @default.
• W2116156965 cites W2084657347 @default.
• W2116156965 cites W2091440810 @default.
• W2116156965 cites W2102591890 @default.
• W2116156965 cites W2105054364 @default.
• W2116156965 cites W2107247352 @default.
• W2116156965 cites W2108235071 @default.
• W2116156965 cites W2111342463 @default.
• W2116156965 cites W2124560610 @default.
• W2116156965 cites W2127760782 @default.
• W2116156965 cites W2130664802 @default.
• W2116156965 cites W2139663727 @default.
• W2116156965 cites W2143756652 @default.
• W2116156965 cites W2146502962 @default.
• W2116156965 cites W2147422161 @default.
• W2116156965 cites W2149634568 @default.
• W2116156965 cites W2152290005 @default.
• W2116156965 cites W2156748957 @default.
• W2116156965 cites W2159114387 @default.
• W2116156965 cites W2171504422 @default.
• W2116156965 cites W2609515889 @default.
• W2116156965 cites W2979923058 @default.
• W2116156965 cites W3145716452 @default.
• W2116156965 doi "https://doi.org/10.1158/1078-0432.ccr-08-1022" @default.
• W2116156965 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19147779" @default.
• W2116156965 hasPublicationYear "2009" @default.
• W2116156965 type Work @default.
• W2116156965 sameAs 2116156965 @default.
• W2116156965 citedByCount "30" @default.
• W2116156965 countsByYear W21161569652012 @default.
• W2116156965 countsByYear W21161569652013 @default.
• W2116156965 countsByYear W21161569652014 @default.
• W2116156965 countsByYear W21161569652016 @default.
• W2116156965 countsByYear W21161569652019 @default.
• W2116156965 countsByYear W21161569652020 @default.
• W2116156965 countsByYear W21161569652021 @default.
• W2116156965 countsByYear W21161569652022 @default.
• W2116156965 countsByYear W21161569652023 @default.
• W2116156965 crossrefType "journal-article" @default.
• W2116156965 hasAuthorship W2116156965A5002073335 @default.
• W2116156965 hasAuthorship W2116156965A5023128779 @default.
• W2116156965 hasAuthorship W2116156965A5031193094 @default.
• W2116156965 hasAuthorship W2116156965A5033407869 @default.
• W2116156965 hasAuthorship W2116156965A5050350842 @default.
• W2116156965 hasAuthorship W2116156965A5054461576 @default.
• W2116156965 hasAuthorship W2116156965A5058771300 @default.
• W2116156965 hasAuthorship W2116156965A5066578976 @default.
• W2116156965 hasAuthorship W2116156965A5067860129 @default.
• W2116156965 hasAuthorship W2116156965A5069441736 @default.
• W2116156965 hasAuthorship W2116156965A5074102777 @default.
• W2116156965 hasAuthorship W2116156965A5090258495 @default.
• W2116156965 hasBestOaLocation W21161569651 @default.
• W2116156965 hasConcept C126322002 @default.
• W2116156965 hasConcept C143998085 @default.
• W2116156965 hasConcept C204232928 @default.
• W2116156965 hasConcept C2776364478 @default.
• W2116156965 hasConcept C2776694085 @default.
• W2116156965 hasConcept C2777478702 @default.
• W2116156965 hasConcept C2780775027 @default.
• W2116156965 hasConcept C71924100 @default.
• W2116156965 hasConceptScore W2116156965C126322002 @default.

• next